Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating [Seeking Alpha]
Fulgent Genetics (NASDAQ:FLGT) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Fulgent Genetics (NASDAQ:FLGT) had its price target raised by analysts at Piper Sandler from $21.00 to $30.00. They now have a "neutral" rating on the stock.
Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Fulgent Genetics Inc (FLGT) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Upward ... [Yahoo! Finance]